A phase III study to assess the efficacy of ZD6474 (ZACTIMA) plus best supportive care versus best supportive care in patients with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer after therapy with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Trial Profile

A phase III study to assess the efficacy of ZD6474 (ZACTIMA) plus best supportive care versus best supportive care in patients with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer after therapy with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEPHYR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 May 2014 Planned End Date changed from 1 Sep 2012 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top